Vislink Technologies Bolsa (NASDAQ: VISL)

Últimas noticias sobre Vislink Technologies (NASDAQ:VISL) Bolsa

Vislink Technologies

Vislink Technologies Inc is a technology business specializing in collecting, delivering, and managing high-quality, live video and associated data from the scene of the action to the viewing screen. It provides solutions for the collection of live news, sports, and entertainment events for the broadcast markets. It also furnishes the surveillance and defense markets with real-time video intelligence solutions using various tailored transmission products. The company provides professional and technical services utilizing a staff of technology experts with decades of applied knowledge and real-world experience in terrestrial microwave, satellite, fiber optic, surveillance, and wireless communications systems delivering a broad spectrum of customer solutions.

Vislink Technologies, Inc. - Common Stock

Vislink Technologies Inc

The Biden administration has launched a trade investigation into Chinese-produced &#8220;legacy&#8221; semiconductors. This action, announced on Monday, could pave the way for higher U.S. tariffs on these essential components used in numerous consumer products.
What Happened: The &#8220;Section 301&#8221; investigation is slated to transition to the incoming administration of President-elect Donald Trump for completion. This could provide Trump with a chance to enforce the hefty 60% tariffs he has previously threatened on Chinese imports, Reuters reported on Monday.
Currently, a 50% U.S. tariff on Chinese semiconductors is set to begin on Jan. 1. The U.S. has also intensified export restrictions on advanced AI and memory chips to China, alongside increasing tariffs on other Chinese goods.
See Also: <a href="https://www.benzinga.com/markets/24/12/42572520/2025-housing-market-looks-like-a-year-of-struggle-for-states-like-builders-now-hold-record-inventory?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;2025 Housing Market Looks Like A Year Of Struggle For States Like …&#8217; – Builders Now Hold Record Inventory</a>
The U.S. Trade Representative&#8217;s office, led by Katherine Tai, explained that the probe seeks to shield market-driven chip producers from China&#8217;s state-driven expansion. Tai highlighted evidence of China&#8217;s attempts to dominate the semiconductor industry, similar to its strategies in other sectors.
The Biden administration will start&nbsp;accepting public comments on the&nbsp;probe on January 6, with a public hearing scheduled for March. The investigation will also evaluate the impact of these chips on critical industries, including defense and automotive sectors.
Why It Matters: This latest probe is part of a broader strategy by the Biden administration to curb China&#8217;s influence in the semiconductor industry. Earlier this month, the administration <a href="https://www.benzinga.com/government/regulations/24/12/42265847/biden-targets-china-with-new-chip-restrictions-nvidia-slides">implemented its third crackdown</a> on China&#8217;s semiconductor sector within three years, citing national security concerns. This initiative imposed export restrictions on 140 Chinese entities, including chip equipment manufacturers such as Naura Technology Group, targeting advanced memory chips and chipmaking tools. As a result, Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) saw its stock trade lower due to potential impacts on its sales in China.
In response, China swiftly retaliated by tightening <a href="https://www.benzinga.com/news/global/24/12/42303132/china-retaliates-against-us-chip-sanctions-tightens-mineral-exports">controls on critical minerals</a> used in chip manufacturing, such as gallium, germanium, and antimony. These materials are crucial for advanced electronics and defense applications. The Chinese Ministry of Commerce justified these measures as necessary for national security, highlighting the escalating tensions between the two nations.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/24/12/42638957/warren-buffetts-timeless-advice-if-youre-gonna-do-dumb-things-because-your-stock-goes-down-you-shouldnt-own-a-stock-at-all?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Warren Buffett's Timeless Advice For Investing $10,000: &#8216;If You're Gonna Do Dumb Things Because Your Stock At All&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Image via Shutterstock

News

Global

Tech

General

NVDA

Biden Administration Initiates Trade Probe On Chinese 'Legacy' Chips

Jefferies analyst David Stanton downgrades Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) from Buy to Hold.

Downgrades

Analyst Ratings

MESO

Jefferies Downgrades Mesoblast to Hold

Despegar.com, Corp. (NYSE:<a href="https://www.benzinga.com/stock/DESP#NYSE">DESP</a>) ("Despegar" or the "Company"), Latin America's leading travel technology company, today announced that it has entered into a definitive merger agreement ("the Agreement") to be acquired by Prosus (Euronext: PRX), a leading global technology company for $19.50 per share in an all cash transaction (the "Transaction"), representing an enterprise value of approximately $1.7 billion for Despegar.
The transaction price represents a premium of approximately 34% over the volume weighted average price of Despegar's share price for the 90 trading days ending on December 20, 2024.
Despegar's Board of Directors has approved the Agreement and has resolved to recommend that Despegar shareholders vote in favor of the adoption of the Agreement and the approval of the merger contemplated thereby. This approval follows the unanimous recommendation of a transaction committee of the Board of Directors comprised solely of independent directors that was formed in connection with the transaction

DESP

Despegar to Be Acquired by Prosus for $1.7B in Cash Deal

Needham analyst Joseph Stringer reiterates Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) from Hold to Hold.

Reiteration

LXRX

Needham Reiterates Hold on Lexicon Pharmaceuticalsto Hold

Compass Point analyst Dominick Gabriele initiates coverage on NCR Atleos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NATL#NYSE">NATL</a>) with a Buy rating and announces Price Target of $57.

Price Target

Initiation

NATL

Compass Point Initiates Coverage On NCR Atleos with Buy Rating, Announces Price Target of $57

HC Wainwright &amp; Co. analyst Raghuram Selvaraju upgrades Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Buy and maintains the price target from $20 to $20.

Upgrades

ACRS

HC Wainwright & Co. Upgrades Aclaris Therapeutics to Buy, Maintains Price Target to $20

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Vanda Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) with a Buy and maintains $18 price target.

VNDA

HC Wainwright & Co. Reiterates Buy on Vanda Pharma, Maintains $18 Price Target

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and maintains $69 price target.

RYTM

HC Wainwright & Co. Reiterates Buy on Rhythm Pharmaceuticals, Maintains $69 Price Target

Market-Moving Exclusives

Exclusives

TELO

EXCLUSIVE: Telomir Pharmaceuticals Tells Benzinga Co. Confirms Copper-Binding Capabilities Of Telomir-1 And Expands Pipeline Into Wilson's Disease

Castellum, Inc. (NYSE-American: CTM) ("Castellum"), a cybersecurity, electronic warfare, and software engineering services company focused on the federal government, announces that its <a href="https://www.globenewswire.com/Tracker?data=2uLrI8261QtiQmeyEX_gy6JpQ-moKeUMas7MX0KiELEefnH75OHV-JXUfPsv_zKI7gHoXxkBqsvA_eImOxN3D6G4PL5vSPCM60jU0LeJn-vqxAiMc5Hvq23f7HgN9H_j">subsidiary Specialty Systems, Inc.,</a> teaming with Castellum's other two subsidiaries <a href="https://www.globenewswire.com/Tracker?data=xuSy8FtCDO83pGRtqv3Bvd1mPpu7go0e-GbTqJOQfJpOv_sGIz-OJqLYw2ishXp8SNb4c4XnqbhR6CDFldnrtW6jI5X0Ly8kGJnXmWf_r7srd0t2OloOpVJX64Fh8CLU">Corvus Consulting, LLC</a> and <a href="https://www.globenewswire.com/Tracker?data=k8X5vM0eJAl01EJ9rJycnEmDk9yQVQVWU5kbUoIek9XS_3bxyu5GYFX64I44ybWTUYMcTU2iovmCpcKa02R-MD1goOgkN92qMYL4z1wzHMwClXsrY-NBB5mNeW7suWDSQclfL1E3M0ECNAUCnxh1Kg==">Global Technology and Management Resources, Inc.,</a> was awarded all four unrestricted domains upon which it submitted proposals. This award is in addition to the three small business domains the Castellum team has already been awarded on One Acquisition Solution for Integrated Services Plus ("OASIS+").
OASIS+ is a suite of government-wide, multi-award contracts designed to support federal agencies' procurement requirements for services-based solutions. With a potential ten-year performance period and no ceiling value, OASIS+ represents a significant opportunity for the Castellum team to expand its support to federal customers.

Government

Regulations

Castellum Secures Major Federal Contract Awards Through OASIS+ Program

GPUS

Hyperscale Data Secures Financing Agreement For Up To $25M In Series G Convertible Preferred Stock

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) with a Buy and maintains $7 price target.

RMTI

HC Wainwright & Co. Reiterates Buy on Rockwell Medical, Maintains $7 Price Target

On Monday, Telomir Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELO#NASDAQ">TELO</a>) announced preclinical findings highlighting the copper-binding potential of its lead compound, Telomir-1, as a promising treatment for Wilson's disease and related disorders. The compound exhibits a binding affinity for copper ions, enabling precise regulation of copper metabolism and interacting with essential ions such as copper, iron, and zinc, the company said.
Recent preclinical studies by Recipharm and Smart Assays reveal Telomir-1's strong copper-binding affinity, enabling precise regulation of copper metabolism and interaction with essential ions.
According to the company, these findings position Telomir-1 as a potential breakthrough therapy for Wilson's disease, a rare disorder caused by ATP7B mutations leading to toxic copper buildup in vital organs.
Offering a safer alternative to current treatments, which have significant side effects and require lifelong adherence, Telomir-1 targets the disease's root cause and may qualify for orphan drug designation.
Telomir is also advancing Telomir-1's therapeutic potential in related areas, including Type 2 diabetes and age-related diseases.
The company is optimizing GMP-grade production for IND-enabling studies scheduled for second quarter of 2025, with an IND submission planned for the fourth quarter and first-in-human clinical trials expected by mid-2026. Efforts also include securing an INAD for pets and exploring Telomir-1's dual applications in human and veterinary medicine.
In line with its ethical practices, Telomir discontinued its osteoarthritis study in dogs after the safety phase due to concerns over inducing the condition. The company is now collaborating with a veterinary institution to design a study using elderly dogs naturally affected by osteoarthritis, advancing its INAD application for pets.
"As we look to 2025, Telomir remains dedicated to its mission," said Erez Aminov, Chairman and CEO. "We are pleased to have secured additional financing at a 20% premium with no warrants, providing the resources needed to continue advancing Telomir-1's development while creating value for our shareholders."
Price Action: TELO shares closed 14.10% higher at $5.18 on Friday.

Biotech

Health Care

EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bms.com%2F&amp;esheet=54170253&amp;newsitemid=20241223250943&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=b5586a81e66ef03f03c233e8008cee0b">Bristol Myers Squibb</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) today announced that the European Commission (EC) has approved Opdivo&#xAE; (nivolumab) plus Yervoy&#xAE; (ipilimumab)for the first-line treatment of adult patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer (mCRC).
"Colorectal cancer is the second leading cause of cancer death in Europe and patients are in need of new treatment options that delay disease progression. Approximately 5-7% of metastatic colorectal cancer patients have MSI-H/dMMR tumors and these patients are less likely to benefit from conventional chemotherapy and typically have poor prognosis outcomes," said Dana Walker, M.D., M.S.C.E., vice president, Opdivo global program lead, Bristol Myers Squibb. "The EC's decision to approve Opdivo plus Yervoy represents a significant milestone for this patient population in the European Union and underscores our commitment to advancing treatment options."

Bristol Myers Squibb Wins EU Approval for New Colorectal Cancer Treatment

DA Davidson analyst Linda Bolton Weiser maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Buy and maintains $81 price target.

DA Davidson Maintains Buy on Estee Lauder Cos, Maintains $81 Price Target

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) with a Buy and maintains $16 price target.

BWAY

HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $16 Price Target

HC Wainwright &amp; Co. analyst Yi Chen initiates coverage on Sanara MedTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTI#NASDAQ">SMTI</a>) with a Buy rating and announces Price Target of $50.

SMTI

HC Wainwright & Co. Initiates Coverage On Sanara MedTech with Buy Rating, Announces Price Target of $50

Telsey Advisory Group analyst Joseph Feldman maintains Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) with a Outperform and maintains $70 price target.

Telsey Advisory Group Maintains Outperform on Kroger, Maintains $70 Price Target

HC Wainwright &amp; Co. analyst Andres Maldonado initiates coverage on enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) with a Buy rating and announces Price Target of $25.

ENGN

HC Wainwright & Co. Initiates Coverage On enGene Holdings with Buy Rating, Announces Price Target of $25

NanoViricides, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#NYSE">NNVC</a>) (the "Company"), says that its broad-spectrum antiviral drug candidate NV-387 is the best weapon to fight a potential bird flu pandemic because the mercurial H5N1 Influenza A virus would not be able to escape the drug.
"Despite all changes, the H5N1 Influenza A virus should remain susceptible to NV-387 because NV-387 mimics the very essential host-side feature that H5N1 continues to use even as it changes," said Anil R. Diwan, Ph.D., President and Executive Chairman of the Company, adding "This drug puts us in a great position to be able to fight a bird flu pandemic should it happen."
WHO has stated "Available virus sequences from human cases [of H5 infection] have shown some genetic markers that may reduce susceptibility to neuraminidase inhibitors (antiviral medicines such as oseltamivir) [NAIs] or endonuclease inhibitors (such as baloxavir marboxil) [PBIs]" in their updated public health assessment of recent Influenza A H5 infections, dated December 20, 2024

NNVC

NanoViricides Claims NV-387 Could Be Key in Fighting Bird Flu Pandemic

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Vislink Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/visl-stock-quote/">VISL</a>) just reported results for the second quarter of 2024.<ul><li>Vislink Technologies reported earnings per share of -93 cents.</li><li>The company reported revenue of $8.70 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/visl-stock-earnings-vislink-technologies-for-q2-of-2024/">VISL Stock Earnings: Vislink Technologies Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

VISL Stock Earnings: Vislink Technologies Reported Results for Q2 2024

Vislink announces appointment of Joseph Lipowski as CTO

Vislink Technologies Q3 Earnings Preview

Here's the major earnings before the open tomorrow

Vislink Technologies GAAP EPS of -$1.22 misses by $0.49, revenue of $7.07M misses by $1.4M

Reports Q3 revenue $7.1M vs $7.2M last year. "We are pleased to report that our year-to-date revenue has increased over 26% compared to the same pe...

Vislink reports Q3 EPS ($1.22) vs (83c) last year.

09:46 EST Vislink (VISL) Technologies trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financi...

Vislink Technologies trading resumes

09:41 EST Vislink (VISL) Technologies trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, marke...

Vislink Technologies trading halted, volatility trading pause

Alliance Global Partners lowered the firm's price target on Vislink (VISL) to $9 from $12 and keeps a Buy rating on the shares. The company reporte...

Vislink price target lowered to $9 from $12 at Alliance Global Partners

Vislink Technologies, Inc. (VISL) Q3 2024 Earnings Call Transcript

AFMD

AZUL

BILI

BLUE

BTAI

CASI

CRIS

CVSI

DTEGY

EONGY

ITRM

KEYUF

KNTNF

LUNR

MKGAF

NICE

NLCP

NTES

OCUL

ONEW

PAVM

PDSB

POLA

PVCT

QBTS

SACH

SIEGY

SPCB

VEON

VISL

WKHS

XNET

Press Releases

Vislink Reports Second Quarter 2024 Financial and Operational Results

Vislink to Participate at the 2024 Gateway Conference on September 4th

Vislink Technologies, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vislink Announces Appointment of Joseph Lipowski as Chief Technology Officer

Vislink to Debut DragonFly V and INCAM-GV Transmitters at IBC 2024

Vislink Launches New Brand Identity and Website to Drive Global Growth and Strengthen Market Leadership

Mather Al-Ali Joins Vislink as Vice President of Sales for Middle East and Africa Region

Vislink to Report Third Quarter 2024 Financial Results on Thursday, November 14, 2024, at 8:30 a.m. ET

Vislink Reports Third Quarter 2024 Financial and Operational Results

Vislink Introduces DragonFly V 5G Miniature Transmitter: Redefining Portable Live Video Streaming

Comments

Vislink Technologies

Noticias

Últimas noticias sobre Vislink Technologies (NASDAQ:VISL) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL